There is a peculiar disconnect at the heart of D-Wave Quantum’s current market narrative. On one side sits a bookings pipeline that has grown more than twelvefold in a single year. On the other, a quarterly revenue figure that missed consensus by nearly a million dollars. Both facts are true, and both are driving the stock’s recent behavior in ways that leave investors parsing which signal matters more.
The latest catalyst arrived in the form of a modest grant from the National Research Council of Canada, worth up to 300,000 Canadian dollars to advance the company’s annealing software for commercial applications. By itself, the sum is trivial. But it slots into a pattern that has been building for weeks: institutional validation, scientific credibility, and corporate partnerships arriving in rapid succession.
A Breakthrough, Then a Disappointment
The sequence of events in early August tells the story. On August 5, D-Wave announced a significant advance in quantum error correction, published in Nature. The very next day, second-quarter results landed with a thud. Revenue came in at $3.07 million against a consensus estimate of $4.03 million. The net loss per diluted share narrowed to $0.13 from $0.55 a year earlier — an improvement, though it still missed the $0.09 loss analysts had penciled in. Gross margin slipped from 63.8 percent to 55.4 percent. The stock dropped 9 percent in response.
That sell-off, however, tells only part of the story. Since the error-correction paper, shares have gained 8.5 percent; since the expanded AT&T collaboration announced around the same time, they are up 16 percent. The market, in other words, is rewarding technological substance over near-term financials.
The Bookings Counter-Narrative
The bull case rests on numbers that don’t appear in the quarterly income statement. First-half 2026 bookings reached $35.5 million, a 1,120 percent surge year over year. Remaining performance obligations — contracted future revenue — jumped 668 percent to $40.7 million. Production revenue from the company’s QCaaS business accounted for 37.3 percent of that segment’s total, and commercial customers contributed 62 percent of quarterly revenue, a meaningful shift away from research institutions.
This is the classic profile of a young, capital-intensive technology company winning contracts whose revenue recognition lags. The orders are real; the billing schedule simply hasn’t caught up.
The Cost of Ambition
The bear case is equally visible in the numbers. EBITDA losses widened from $20 million to $37 million. First-half operating expenses doubled from $53.6 million to $111.5 million. The price-to-sales ratio sits at an eye-watering 610. Short interest hovers near 20 percent, a substantial bet against the stock — even as the number of hedge funds holding positions ticked up from 22 to 26.
Should investors sell immediately? Or is it worth buying D-Wave Quantum?
Wall Street’s consensus remains “Strong Buy” with an average price target of $34.67. Wedbush sees $40, Rosenblatt $43. Those targets presuppose that bookings growth eventually translates into recognized revenue — a promise, not yet a balance-sheet reality.
The Political Tailwind
D-Wave is also riding a wave of government support that extends well beyond Ottawa. The company is among four quantum computing firms — alongside Infleqtion, PsiQuantum, and Quantinuum — that have doubled their annual Washington lobbying spending to $2.2 million, a response to the $2 billion in federal investments announced in May. As one Cato analyst put it, when access to funding pools becomes decisive, you play the game.
Last Friday, the National Science Foundation approved $15 million for the QuantumCT-Engine program in Connecticut, led by UConn and Yale, with the state adding $121 million. D-Wave and Quantinuum are industrial partners in that initiative, which targets applications in defense, biotechnology, and finance. Industry projections see the global quantum technology market reaching $200 billion by 2040 — a figure that explains why governments and corporations alike are eager to establish early positions.
Where the Stock Stands
The share price reflects the tension. At €18.30, the stock sits almost exactly on its 50-day moving average of €18.36, suggesting consolidation after recent swings. It has climbed 15 percent over the past month but remains down 19 percent year to date. The gap to the 52-week high of €40.41 stands at 55 percent, a reminder that last year’s euphoria has not returned. Annualized volatility of 104 percent underscores how nervously the market trades this name. Those who bought at the spring low of €11.12 are sitting on a comfortable intermediate gain.
The company holds $546.2 million in cash against just $48 million in debt, giving it ample runway to attempt the transition from scientific promise to commercial reality. Management will have opportunities to press that case at the Needham 7th Annual Virtual Semiconductor & SemiCap Conference on August 20 and the Deutsche Bank 2026 Technology Conference on August 27.
The fundamental question remains whether a company whose lobbying spend is growing faster than its quarterly revenue represents a sector in transition or a house of cards. D-Wave’s bookings trajectory suggests the former, but the revenue recognition problem won’t be argued away at investor conferences. The direction of travel looks right; the timing remains the open question.
Ad
D-Wave Quantum Stock: Buy or Sell?! New D-Wave Quantum Analysis from August 16 delivers the answer:
The latest D-Wave Quantum figures speak for themselves: Urgent action needed for D-Wave Quantum investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 16.
D-Wave Quantum: Buy or sell? Read more here...
